ANGIZAAR-H Tablet

ឱសថនេះប្រើសំរាប់ព្យាបាលជម្ងឺសម្ពាធឈាមឡើង។

<កំរិតនិងរបៀបប្រើ>

- លេប1គ្រាប់ ក្នុង1ថ្ងៃ (កំរិតធម្មតា)

- ក្រោយពេលព្យាបាល3សប្ដាហ៍ បើសភាពជម្ងឺមិនធូរស្បើយទេ អាចប្រើ2គ្រាប់ក្នុង1ថ្ងៃ

- មិនអនុញ្ញាតអោយប្រើលើសពី2គ្រាប់ក្នុង1ថ្ងៃ។

For the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.

Dosage

When blood pressure is not adequately controlled with losartan monotherapy, the prescription may be switched to this medicine once daily. If the blood pressure remains uncontrolled after about 3 weeks of therapy, the dose may be increased to 2 tablets once daily.

The usual dose of this medicine is 1 tablet once daily. More than 2 tablets once daily is not recommended. The maximal antihypertensive effects attained about 3 weeks after initiation of therapy.

ហាមប្រើ៖

- អ្នកជម្ងឺងាយមានប្រតិកម្មជាមួយសមាសធាតុផ្សំណាមួយនៃឱសថនេះ

- អ្នកជម្ងឺគ្មានទឹកនោម ឬ ទល់នោម (Anuria)។

In patients who are hypersensitive to any component of this product.

Because of the hydrochlorothiazide component, this product is contra-indicated in patients with anuria or hypersensitivity to other sulfonamide derived drugs.

ផលរំខានខ្លះៗ: ការប្រើឱសថនេះមានភាពអនុគ្រោះល្អ។

Losartan Potassium - hydrochlorothiazide has been evaluated for safety in essential hypertension. In clinical trials with losartan potassium hydrochlorothiazide, no adverse experiences peculiar to this combination drug have been observed. Adverse experiences have been limited to those that were reported previously with losartan potassium and/or hydrochlorothiazide. In general, treatment with losartan potassium-hydrochlorothiazide was well tolerated.

No significant drug-drug pharmacokinetic interactions have been found. When administered with barbiturates, or narcotics, alcohol there may be potentiation of orthostatic hypotension.

Fetal/neonatal Mortality:

Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, this tablet should be discontinued as soon as possible.

ការប្រុងប្រយ័ត្ន៖

- ហាមប្រើចំពោះស្ត្រីមានផ្ទៃពោះ ព្រោះអាចបណ្ដាលអោយទារកក្នុងផ្ទៃនិងកូនទើបកើតស្លាប់

- អ្នកមានសម្ពាធឈាមចុះ

- ចំពោះអ្នកដែលខ្សោយមុខងារថ្លើម

- ប្រុងប្រយ័ត្នចំពោះកំរិតជាតិប៉ូតាស្យូមនៅក្នុងឈាម

- អ្នកជម្ងឺខ្សោយតំរងនោម មិនគួរប្រើឱសថនេះទេ។

Hypotension - Volume Depleted Patients:

In patients who are intravascularly volume-depleted, symptomatic hypotension may occur after initiation of therapy with this medicine. This condition should be corrected prior to administration of this medicine.

Impaired Hepatic Function:

This medicine is not recommended for patients with hepatic impairment who require titration with losartan. The lower starting dose of losartan recommended for use in patients with hepatic impairment cannot be given using this medicine.

Precautions: General:

In double-blind clinical trials of various doses of losartan potassium and hydrochlorothiazide, the incidence of hypertensive patients who developed hypokalemia was 6.7% versus 3.5% for placebo; the incidence of hyperkalemia was 0.4%. No patient discontinued due to increases or decreases in serum potassium.

In patients treated with various doses of losartan and hydrochlorothiazide, there were also a dose-related decrease in the hypokalemic response to hydrochlorothiazide as the dose of losartan was increased, as well as dose related decreases in serum uric acid with increasing doses of losartan. Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

In Patients with Renal Impairment: The usual regimens of therapy with this medicine is followed as long patient’s creatinine clearance is >3mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so this medicine is not recommended. Thiazides should be used with caution in severe renal disease.